Natco Pharma Reports Q3FY26 Results with ₹705.4 Crore Revenue and ₹151.3 Crore Net Profit
NiveshIQ
NSE: NATCOPHARM · Pharma
NATCO Pharma Ltd.
₹815.35▼ ₹3.30 (-0.40%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on NATCOPHARM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About NATCO Pharma Ltd.
NATCO Pharma Limited is a pharmaceutical company that engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients, and intermediates in India, the United States, and internationally. The company's core business includes offerings in various therapeutic areas, such as oncology, central nervous system, pain management, and cardiovascular care, with a significant presence in the oncology segment. Key revenue drivers for NATCO Pharma include its formulations business, which contributes a substantial portion of its revenue, as well as its active pharmaceutical ingredients and contract manufacturing services. Recently, the company reported a 57% year-over-year decline in net profit to ₹206.5 crore in Q1 FY27, despite im
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹3,999 Cr +47.70% | ₹4,430 Cr +10.80% | ₹4,078 Cr -7.90% |
| EBITDA Margin | 43.86% | 49.57% | 42.52% |
| Net Profit | ₹1,388 Cr +94.10% | ₹1,883 Cr +35.70% | ₹1,418 Cr -24.70% |
| EPS | ₹77.51 | ₹105.26 | ₹79.20 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Natco Pharma Reports Q3FY26 Results with ₹705.4 Crore Revenue and ₹151.3 Crore Net Profit
Natco Pharma Share Price - Live NSE: NATCOPHARM Stock Price & Chart
🔒
+ 3 more stories about NATCO Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹735 Cr, PAT ₹206 Cr, EPS ₹11.53, EBITDA margin 33.4%. Growth context: revenue QoQ -0.5%, PAT QoQ -23.2%. Street verdict: strong beat, revenue surprise -3.0%, PAT surprise +43.4%.
Key drivers for NATCOPHARM over the next 2–4 quarters will include product pipeline delivery, domestic demand, export mi...
In FY26, NATCOPHARM reported revenue of ₹4, 078 Cr, PAT of ₹1, 418 Cr, an EBITDA margin of 42.5%, and EPS of ₹79.20, rep...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for NATCOPHARM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track NATCOPHARM alongside your other holdings
Unlock full NATCOPHARM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for NATCO Pharma Ltd.?
NiveshIQ detects active intelligence signals for NATCO Pharma Ltd. (NATCOPHARM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for NATCO Pharma Ltd.?
NATCO Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹2,104,361.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.